Last updated: July 20, 2026
ecutive summary: No litigation summary can be produced for “GRUNENTHAL GMBH v. TEVA PHARMACEUTICALS, INC. | 2:24-cv-06104” because the docket record content (complaint, patents-in-suit, asserted Orange Book listing, procedural posture, and any settlement terms) is not provided. Per constraints, no partial or speculative case analysis is included.
2:24-cv-06104 GRUNENTHAL v TEVA: What does the complaint allege and which patents are asserted?
No case specifics are included because the asserted patents, Orange Book reference product, and claims cannot be verified from the prompt.
What patents are listed as “patents-in-suit” in 2:24-cv-06104
Not determinable from the provided input.
What drug, dosage form, and formulation the dispute targets
Not determinable from the provided input.
What is the litigation timeline for GRUNENTHAL GMBH v TEVA in 2:24-cv-06104?
No procedural timeline can be stated without docket events (filed date, service, scheduling order, claim construction, summary judgment, trial dates, or status reports).
Key docket milestones typically driving Paragraph IV cases
Not determinable from the provided input.
Has TEVA filed a Paragraph IV notice for the Orange Book-listed drug in 2:24-cv-06104?
No Orange Book listing or notice basis is provided in the prompt, so the Paragraph IV predicate cannot be confirmed.
What triggers the Hatch-Waxman infringement action in this case
Not determinable from the provided input.
How strong is Grunenthal’s patent estate in 2:24-cv-06104?
No asserted patent numbers or independent claim themes are provided, so strength analysis (validity and infringement likelihood) cannot be performed.
Method-of-use vs. formulation vs. process patents
Not determinable from the provided input.
Claim construction risk points
Not determinable from the provided input.
What defenses does TEVA raise in 2:24-cv-06104 and how do they map to asserted claims?
No answer, invalidity contentions, noninfringement positions, or JMOL/Daubert motions are provided.
Anticipation, obviousness, indefiniteness, and noninfringement frameworks
Not determinable from the provided input.
What is the current status of 2:24-cv-06104 and what happens next?
No status (dismissal, stay, Markman scheduled/completed, settlement, or remand) is provided.
Settlement or consent judgment impact
Not determinable from the provided input.
What generic entry risks exist for TEVA tied to 2:24-cv-06104?
No entry date, FDA approval status, or product launch posture is stated.
Design-around and FDA approval dependencies
Not determinable from the provided input.
How does this case compare with other Grunenthal vs. Teva Hatch-Waxman litigations?
No comparison set or related dockets are provided, so no accurate cross-case mapping can be done.
Key Takeaways
- A litigation summary and analysis cannot be produced from the provided case caption alone.
- No asserted patent list, Orange Book linkage, procedural posture, or outcomes are specified, so no reliable, decision-grade conclusions can be stated.
FAQs
- What patents-in-suit are associated with docket 2:24-cv-06104?
- What Orange Book listing and FDA reference product underlie Grunenthal’s claims?
- Is the case stayed, settled, or proceeding to claim construction or trial?
- What are TEVA’s core invalidity and noninfringement arguments (anticipation/obviousness/indefiniteness)?
- How does the case affect potential TEVA generic launch timing and exclusivity exposure?
References
None.
